These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8352178)

  • 1. Impact of tissue plasminogen activator and heparin versus heparin alone on quantitative coronary angiographic findings in myocardial infarction. The Toronto Tissue Plasminogen Activator Trial Study Group.
    Haq A; Morgan CD; Wilson RF; Daly PA; Baigrie RS; White CW; Roberts R; Gent M; Armstrong PW
    Am J Cardiol; 1993 Aug; 72(5):379-83. PubMed ID: 8352178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.
    GUSTO Angiographic Investigators
    N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction.
    Bleich SD; Nichols TC; Schumacher RR; Cooke DH; Tate DA; Teichman SL
    Am J Cardiol; 1990 Dec; 66(20):1412-7. PubMed ID: 2123602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
    Johns JA; Gold HK; Leinbach RC; Yasuda T; Gimple LW; Werner W; Finkelstein D; Newell J; Ziskind AA; Collen D
    Circulation; 1988 Sep; 78(3):546-56. PubMed ID: 3136953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronary patency, infarct size and left ventricular function after thrombolytic therapy for acute myocardial infarction: results from the tissue plasminogen activator: Toronto (TPAT) placebo-controlled trial. TPAT Study Group.
    Morgan CD; Roberts RS; Haq A; Baigrie RS; Daly PA; Gent M; Armstrong PW
    J Am Coll Cardiol; 1991 Jun; 17(7):1451-7. PubMed ID: 1903404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group.
    Thompson PL; Aylward PE; Federman J; Giles RW; Harris PJ; Hodge RL; Nelson GI; Thomson A; Tonkin AM; Walsh WF
    Circulation; 1991 May; 83(5):1534-42. PubMed ID: 1902404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).
    Arnout J; Simoons M; de Bono D; Rapold HJ; Collen D; Verstraete M
    J Am Coll Cardiol; 1992 Sep; 20(3):513-9. PubMed ID: 1512327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction.
    Topol EJ; George BS; Kereiakes DJ; Stump DC; Candela RJ; Abbottsmith CW; Aronson L; Pickel A; Boswick JM; Lee KL
    Circulation; 1989 Feb; 79(2):281-6. PubMed ID: 2492454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of continued rt-PA administration on the residual stenosis after initially successful recanalization in acute myocardial infarction--a quantitative coronary angiography study of a randomized trial.
    Serruys PW; Arnold AE; Brower RW; de Bono DP; Bokslag M; Lubsen J; Reiber JH; Rutsch WR; Uebis R; Vahanian A
    Eur Heart J; 1987 Nov; 8(11):1172-81. PubMed ID: 3121334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial.
    Califf RM; Topol EJ; George BS; Boswick JM; Lee KL; Stump D; Dillon J; Abbottsmith C; Candela RJ; Kereiakes DJ
    Circulation; 1988 May; 77(5):1090-9. PubMed ID: 2966016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction.
    Topol EJ; Califf RM; George BS; Kereiakes DJ; Rothbaum D; Candela RJ; Abbotsmith CW; Pinkerton CA; Stump DC; Collen D
    Circulation; 1988 May; 77(5):1100-7. PubMed ID: 2966017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of late coronary thrombolysis (recombinant tissue-type plasminogen activator) in preserving left ventricular function in acute myocardial infarction.
    Villari B; Piscione F; Bonaduce D; Golino P; Lanzillo T; Condorelli M; Chiariello M
    Am J Cardiol; 1990 Dec; 66(19):1281-6. PubMed ID: 2123072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.
    Van de Werf F; Arnold AE
    BMJ; 1988 Nov; 297(6660):1374-9. PubMed ID: 3146370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS).
    Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
    J Am Coll Cardiol; 1988 Sep; 12(3):581-7. PubMed ID: 3042835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin-induced prolongation of partial thromboplastin time after thrombolysis: relation to coronary artery patency. HART Investigators.
    Hsia J; Kleiman N; Aguirre F; Chaitman BR; Roberts R; Ross AM
    J Am Coll Cardiol; 1992 Jul; 20(1):31-5. PubMed ID: 1607535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
    Lincoff AM; Topol EJ; Califf RM; Sigmon KN; Lee KL; Ohman EM; Rosenschein U; Ellis SG
    Am J Cardiol; 1995 May; 75(14):871-6. PubMed ID: 7732992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.
    Hsia J; Hamilton WP; Kleiman N; Roberts R; Chaitman BR; Ross AM
    N Engl J Med; 1990 Nov; 323(21):1433-7. PubMed ID: 2122251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombolysis with intravenous human recombinant tissue-type plasminogen activator in acute myocardial infarction: the European experience.
    de Bono DP
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):75B-78B. PubMed ID: 2959717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lessons from the European Cooperative recombinant tissue-type plasminogen activator (rt-PA) versus placebo trial.
    Van de Werf F
    J Am Coll Cardiol; 1988 Dec; 12(6 Suppl A):14A-19A. PubMed ID: 3142943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of a single intravenous bolus injection of tissue-type plasminogen activator in acute myocardial infarction. Bolus Dose-Escalation Study of Tissue-Type Plasminogen Activator (BEST) Investigators.
    Hackett D; Andreotti F; Haider AW; Brunelli C; Shahi M; Fussell A; Buller N; Foale R; Lipkin D; Caponnetto S
    Am J Cardiol; 1992 Jun; 69(17):1393-8. PubMed ID: 1590225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.